BenResearch_OR said:The bulks-list asymmetry was the piece I had missed entirely.
Pushing back on BenResearch_OR here. The counter-case has not been addressed. Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this board is supposed to avoid.
BenResearch_OR said:The bulks-list asymmetry was the piece I had missed entirely.
True, and it depends on a baseline nobody has stated. Without knowing where someone started, the same number can be an excellent result or a disappointing one.
BenResearch_OR said:The bulks-list asymmetry was the piece I had missed entirely.
Bookmarking. The distinction being drawn above is the one nobody else makes. Printing the relevant bit and taking it with me.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsClinical perspective, offered as context rather than as advice. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.
Ask again with the specifics and you will get a better answer than this one.
Dr.NutriCornell said:Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…
Mine went the same way, slower. The detail I would add is minor and it is already implied above.